RRD-251 hydrochloride is a small molecule disruptor of Rb/Raf-1 interaction, potently and selectively disrupts the Rb/Raf-1 (IC50=77 nM) but not Rb/E2F, Rb/prohibitin, Rb/cyclin E, and Rb/HDAC binding.

RS 17053 hydrochloride is a potent and selective α1A adrenoceptor antagonist, with a pKi value of 9.1 in native cell membrane and a pA2 value of 9.8 in functional assays.

RSK2-IN-20 is a potent, selective, and durable inhibitpr of RSK2 with IC50 of 47 nM.

RSV inhibitor compound 1 is a novel potent, orally bioavailable RSV fusion inhibitor with EC50 of 2 nM (RSV Long strain infected HEp-2 cells) without significant cytotoxicity (CC50>100 uM).

RSV604 R enantiomer is the R-enantiomer of RSV604, which is a potent respiratory syncytial virus (RSV) inhibitor targeting the nucleocapsid protein, is less active against RSV..

RSV604 racemate is a racemic mixture, shows less potency against strains of respiratory syncytial virus (RSV) than the S-isomer.

RSV-IN-1 is a human respiratory syncytical virus (hRSV) inhibitor, with an IC50 of 0.11 μM.

RTA-408 is a synthetic triterpenoid that potently activates the antioxidative transcription factor Nrf2 and inhibits the proinflammatory transcription factor NF-κB.

RTC-30 is an orally active, dual pathway inhibitor of PI3K-AKT and RAS-ERK signaling via putative activation of the tumor suppressor PP2A, exhibits GI50 of 15 uM against H1650 lung adenocarcinoma cells.

RTC-5 is a dual pathway inhibitor of PI3K-AKT and RAS-ERK signaling via putative activation of the tumor suppressor PP2A, exhibits GI50 of 12.6 uM against H1650 lung adenocarcinoma cells.

RU 24969 hemisuccinate is a potent SR-1A/SR-1B and moderate SR-2C agonist that may also release serotonin.

RU1968 is a potent, cross-species sperm-specific Ca2+ channel CatSper inhibitor that is selective for CatSper over Slo3.

RU-302 is a small molecule pan-TAM inhibitor that targets the TAM Ig1-Gas6 interface, blocks Gas6-dependent TAM activation.

RU-505 is an effective inhibitor of the Aβ42-fibrinogen interaction with IC50 of 2.72 uM in FP assays.

RU-A1 is a novel potent BMI1 inhibitor that targets cellular self-renewal in hepatocellular carcinoma (HCC).

Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).

Rufloxacin is a fluoroquinolone antibiotic.

Runcaciguat is a potent soluble guanylyl cyclase (sGC) stimulator/activator..

Rupatadine is a dual histamine H1 and PAF antagonist

Rupintrivir (AG-7088, AG7088) is a potent, irreversible inhibitor of human rhinovirus 3C protease, inhibits the replication of all HRV serotypes with EC50 of 23 nM and EC90 of 82 nM.

RU-SKI 43 Hcl is a small molecule inhibitor of Hhat(Hedgehog acyltransferase), the enzyme responsible for the attachment of palmitate onto Shh.

Rutin hydrate is a flavonol glycoside, able to cross the blood-brain barrier, and acts by inhibiting JNK and ERK1/2 activation and activating mTOR signalling.

RV1088 is a potent narrow spectrum kinase inhibitor that target p38, c-Src, Syk or JAK individually, dose-dependently reduces TNF-α levels in LPS-activated macrophages with IC50 of 0.63 nM.

RV-1729 is a potent, selective PI3Kδ inhibitor with IC50 of 12 nM, 2-fold selectivity for PI3Kδ relative to PI3Kγ and 16-fold over PI3Kα.

RV521 is a potent, orally active, small-molecule inhibitor of RSV fusion, demonstrates potent antiviral activity across multiple strains of RSV in vitro..

RVX2135 is a novel potent and orally bioavailable inhibitor of Brd2, Brd3, Brd4, and BrdT with IC50 of 1.31, 0.58, 0.44, and 1.58 uM, respectively.

RVX-297 is a novel orally active, BD2 selective, BET bromodomain inhibitor with Alpha Screen IC50 of 0.08, 0.05 and 0.02 uM for BRD2 (BD2), BRD3 (BD2) and BRD4 (BD2), respectively.

RX-3117 is an orally available and potent DNA synthesis inhibitor with potential antineoplastic activity.

Ryanodine is a cell permeant ryanodine receptor modulator. Ryanodine can either stimulate or inhibit Ryanodine-mediated Ca2+ release depending on its concentrations. Poisonous diterpenoid found in Ryania speciosa.

Ryuvidine is a potent, selective CDK4 inhibitor with IC50 of 6.0 uM, displays >30-fold selectivity over CDK2 (IC50>100 uM).

S107 is a RyR-selective 1,4-benzothiazepine derivative that stabilizes RyR2 channels by enhancing the binding affinity of calstabin2 to mutant and/or PKA-phosphorylated channels.

S119-8 is a novel broad spectrum inhibitor of influenza virus replication (IC50=1.43 nM) by targeting the viral Nucleoprotein (NP), with no detectable cytotoxicity (CC50>50 uM).

S130 (ATG4B inhibitor S130) is a potent, specific ATG4B inhibitor with IC50 of 3.24 uM, shows strong affinity (Kd=4 uM) and specifically suppresses the activity of ATG4B, but not other proteases.

S 18986 is a selective, orally active, brain penetrant positive allosteric modulator of AMPA-type receptors. S 18986 shows cognitive enhancing properties in rodents. S 18986 activates the release of noradrenaline and acetylcholine in rat hippocampus and enhances rat memory in object-recognition tests.

S1p receptor agonist 1 is an S1P receptor agonist extracted from patent WO 2015039587 A1, compound example 2.

S1P1 Agonist 8 is a potent, selective, orally bioavailable S1P1 receptor agonist with EC50 of 35 nM (S1P1 internalization), >100-fold selectivity over against receptor subtypes S1P2-5.

S-2101 is a potent lysine-specific demethylase 1 (LSD1) inhibitor with Ki of 0.61 uM.

S29434 (S 29434) is a highly potent, selective, cell-active inhibitor of Quinone reductase 2 (QR2) with IC50 of 5-16 nM, shows good selectivity for QR2 over QR1.

S-3448 is a potent, specific soluble guanylate cyclase (sGC) activator with EC50 of 0.68 uM, preferentially activates the NO-insensitive heme-oxidized form of sGC.

S3I-M2001 (Bromohydroxyacetone phosphate) is an oxazole-based peptidomimetic of the STAT3 SH2 domain-binding phosphotyrosine peptide that selectively disrupts active STAT3:STAT3 dimers.

S44563 is a potent, dual Bcl-2/Bcl-XL inhibitor with IC50 of 131 and 140 nM, respectively.

S44819 (S 44819, Egis-13529) is a novel potent, competitive, selective antagonist of the α5-GABAAR with Kd of 221 nM, IC50 of 585 nM (α5β2γ2).

S55746 hydrochloride is a potent, orally active and selective BCL-2 inhibitor, with Kis and Kds of 1.3 nM, 520 nM and 3.9 nM, 186 nM for BCL-2 and BCL-XL, respectively. S55746 hydrochloride has antitumor activity.

S55746 (BLC201) is a potent, orally active and selective BCL-2 inhibitor, with a Ki of 1.3 nM and a Kd of 3.9 nM. S55746 (BLC201) has antitumor activity with low toxicity[1].

S63845 is a potent and selective myeloid cell leukemia 1 (MCL1) inhibitor; binds human MCL1 with a Kd of 0.19 nM.

S6K-18 is a highly selective inhibitor of S6K1, with an IC50 of 52nM.

S-99 inhibits LPS-induced TNFa release assay in vivo

SA 47 is a selective and potent inhibitor of fatty acid amide hydrolase (FAAH) and carbamate.

Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.

Safinamide (EMD 1195686; FCE 26743) selectively and reversibly inhibits MAO-B with IC50 of 98 nM, exhibits 5918-fold selectivity against MAO-A.

sAJM-589 is a novel, potent small molecule Myc inhibitor that disrupts the Myc-Max leucine-zipper heterodimer with IC50 of 1.8 uM.

SAK3 (T-VGCC enhancer SAK3) is a potent, orally acitve enhancer of T-type voltage-gated Ca2+ channel (T-VGCC), enhances CaV3.1 and CaV3.3, but not CaV3.2 activity at concentrations of 0.01-10 nM in neuro2A cells in vitro.

Salbutamol is an agonist of the β2-adrenergic receptor (β2-AR; Kd = 759 nM in a radioligand binding assay using CHO cells expressing the human receptor).

Salidroside, a phenylpropanoid glycoside isolated from Rhodiola rosea, has been reported to have a broad spectrum of pharmacological properties.

SALL4 peptide FFW (RRKFAKFQWI, FFW peptide) is a potent therapeutic SALL4 peptide antagonist of SALL4-NURD (nucleosome remodeling deacetylase) interaction with target affinity of 23 nM.

Salvianolic acid A acts as scavengers of reactive oxygen species, reduces the adherence of leukocytes to endothelial cells, inhibits matrix metalloproteinases and inflammation.

Samatasvir (IDX719) is a highly potent, selective inhibitor of HCV NS5A that effectively inhibits HCV genotype 1-5 replicons with EC50 of 2-24 pM.

SAMT-247 potent HIV-1 nucleocapsid protein NCp7 inhibitor with EC50 of 0.6 uM with low cellular toxicity (TC50>100 uM) in cultured and primary cells.

San78-130 is a potent, selective activin receptor-like Kinase 1 (ALK1) inhibitor with IC50 of 62 nM, with greater selectivity compared with L-783277.

SAN9812 (Carnostatine) is a potent, highly selective, competitive inhibitor of Carnosinase 1 (CN1) activity with Ki of 11 nM.

Sapropterin Dihydrochloride, a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4), is a phenylalanine hydroxylase activator.

SAR-100842 (SAR100842) is a potent, selective, orally available antagonist of the Lysophosphatidic Acid 1 Receptor (LPA1 receptor) with IC50 of 31 nM in β-arrestin assays.

SAR-216471 is a potent, highly selective, intravenous and oral, reversible P2Y12 receptor antagonist with binding IC50 of 17 nM.

SAR260301 (SAR-260301, SAR 260301) is a potent, selective, ATP-competitive PI3Kβ inhibitor with IC50 of 52 nM in TR-FRET assays, with littile to no actiivty against PI3Kα/γ/δ (IC50=1,869/>10,000/403 nM, respectively).

SAR405 is a highly potent and selective PI3K class III isoform Vps34 inhibitor with IC50 of 1.2 nM, inhibits the formation of autophagosomes in GFP-LC3 cells with IC50 of 4 nM.

SAR407899 Hcl is a potent, ATP-competitive ROCK inhibitor woth Ki value of 36 nM/41 nM for human ROCK/Rat ROCK respectively.

SAS-0132 (SAS132) is a novel potent, subtype-selective, brain penetrant sigma 2 receptor/PGRMC1 ligand with Ki of 90 nM, 9-fold selectivity over sigma 1 receptors.

Satraplatin (BMS-182751, BMY-45594, JM-216) is a platinum-based antineoplastic agent that binds to guanine residues in DNA, inhibits DNA replication and transcription, leads to subsequent apoptosis.

Sauristolactam, a natural aristolactam isolated from aerial portions of Saururus chinensis, has significant neuroprotective activity against glutamate-induced toxicity in primary cultured rat cortical cells. Sauristolactam also inhibits the receptor activ

SB 204990 is a potent and specific inhibitor of ATP citrate lyase (ACLY) enzyme.

SB 206553 is a potent and selective 5-HT2B/5-HT2C receptor antagonist with pA2 of 8.89 for rat 5-HT2B, pKi of 7.92 for human 5-HT2C, displays >80-fold selectivity over other 5-HT receptor subtypes.

SB 222200 is a selective, reversible and competitive antagonist of human NK-3 receptor(Ki=4.4 nM) that effectively crosses the blood-brain barrier.

SB 242084 is a potent and selective antagonist of 5-HT2C receptor.

SB 737050A is a potent, selective 5-HT6 receptor antagonist to prevent relapse intio addiction..

SB02024 is a novel highly potent, selective, ATP competitive, orally active inhibitor of vacuolar protein sorting 34 (Vps34) with Kd of 1 nM, >1000 times selective towards other PI3K isoenzymes; SB02024 is also highly selective at 1 uM in the DiscoveRx ScanMax panel of 468 kinases; reduces the number of GFP-2xFYVE puncta with IC50 of 14 nM, induces a dose-dependent increase in levels of NCOA4 and p62; blocks autophagy in vitro and reduces xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7; also significantly potentiates cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro.

SB-258585 is a potent, selective and orally active 5-HT6 receptor antagonist with Ki of 8.9 nM, >160-fold selectivity over other 5-HT receptor subtypes.

SB269652 is a potent, selective, negative allosteric modulator of dopamine D2 and D3 receptors, abolishes specific binding of [3H]nemanopride and [3H]spiperone to CHO-transfected D3 receptors with IC50 of1.86 and 0.18 nM.

SB271046 Hcl is a potent, selective and orally active 5-HT6 receptor antagonist with pKi of 8.9.

SB273005 is a potent integrin inhibitor with Ki of 1.2 nM and 0.3 nM for αvβ3 receptor and αvβ5 receptor, respectively.

SB290157 trifluoroacetate is a potent and selective C3a receptor antagonist with an IC50 of 200 nM.

SB-334867 is a selective non-peptide orexin OX1 receptor antagonist with a pKb value of 7.2.

SB-334867 is a selective orexin-1 (OX1) receptor antagonist.

SB-399885 is a potent, selective, brain penetrant 5-HT6 receptor antagonist with pKi of 9.11 and 9.02 for human recombinant and native 5-HT6 receptors.

SB408124 is a non-peptide antagonist for OX1 receptor with Ki of 57 nM and 27 nM in both whole cell and membrane, respectively; exhibits 50-fold selectivity over OX2 receptor.

SB-435495 is a potent, orally active inhibitor of Lp-PLA2 with IC50 of 0.06 nM.

SB-612111 is a potent, selective nociceptin/orphanin FQ receptor (NOP receptor) antagonist with Ki of 0.33 nM.

SB-674042 is a potent and selective non-peptide orexin OX1 receptor antagonist (Kd = 3.76 nM); exhibits 100-fold selectivity for OX1 over OX2 receptors.

SB-699393 is a potent, selective and CNS penetrant B-Raf inhibitor with Kd of 7.2 nM.

SB772077B (SB-772077B, SB77, SB-772077-B) is a potent, selective Rho kinase (ROCK) inhibitor with IC50 of 5.6 nM and 6.0 nM for ROCK1 and ROCK2, respectively.

SBE-β-CD (Sulfobutylether-β-Cyclodextrin; Captisol) is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs; Captisol is the trademark of SBE-β-CD registered by Ligand Pharmaceuticals.

SBI-425 (SBI425) is a potent, selective, orally bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor with IC50 of 16 nM, shows high selectivity over other alkaline phosphatases including IAP and PLAP.

SBI-477 is a chemical probe that coordinately inhibits triacylglyceride (TAG) synthesis and enhances basal glucose uptake in human skeletal myocytes with EC50 of 100 nM and 1 uM, respectively.

SBI-993 is an analog of SBI-477 that shows improved potency and suitable pharmacokinetic properties for in vivo bioavailability

S-C025 is a highly potent antagonist of oxoeicosanoid receptor (OXE receptor) with IC50 of 0.12 nM, inhibits 5-oxo-ETE-induced calcium mobilization in human neutrophils..

S-C025 is a highly potent antagonist of oxoeicosanoid receptor (OXE receptor) with IC50 of 0.12 nM.

SC144 is an orally active small-molecule gp130 inhibitor.

SC-236 (SC58236) is a potent, selective, orally active inhibitor of COX-2 with IC50 of 10 nM.

SC-560 is a member of the diaryl heterocycle class of cyclooxygenase (COX) inhibitors which includes celecoxib (Celebrex™) and rofecoxib (Vioxx™).

SC-68448 (SC68448) is a potent, selective peptidomimetic antagonist of the integrin αvβ3 with IC50 of 1 nM, 100-fold selectivity over αIIbβ3.

SCH 412348 is a potent and highly selective A2A receptor competitive antagonist with Ki of 0.6 nM.

SCH 529074 is a small molecule mutant p53 reactivator that binds p53 DNA binding domain with Kd of 1-2 uM.

SCH 54292 is a potent Ras-GEF interaction inhibitor with IC50 of 0.7 uM..

SCH 546738 is a novel, potent and non-competitive small molecule CXCR3 antagonist with Ki of 0.4 nM .

SCH 900229 is a potent and presenilin 1 selective, and orally active inhibitor of γ-secretase (Aβ40 IC50=1.3 nM).

SCH-28080 is a potent, orally active, reversible inhibitor of gastric H+,K+-ATPase with IC50 of 20 nM.

SCH-527123 is a potent antagonist of both CXCR1 and CXCR2 with IC50 of 42 nM and 3 nM, respectively.

Sclerotigenin is a natural diazepine originally isolated from P. sclerotigenum that acts as an insect growth regulator.1 It reduces the growth rate of first instar H. zea larvae by 42% relative to controls when administered in the standard test diet at 20

Scopine hydrochloride (6,7-Epoxytropine hydrochloride) is the metabolite of anisodine, which is a α1-adrenergic receptor agonist and used in the treatment of acute circulatory shock.

Scytonemin is a marine natural product that inhibits PLK1 with IC50 of 2 uM against recombinant enzyme, shows similar potentcy for Myt1, Chk1,Cdk1/cyclin B and PKCβ2, less potent against PKA and Tie2.

SD-06 is a p38 MAP kinase inhibitor; inhibits p38α with an IC50 value of 170 nM and inhibits LPS-stimulated TNF-release in rats (83% inhibition at 1mg/kg, po).

SD-1029 (NSC 371488) is a potent inhibitor of Stat3 activation, suppresses EGFP-Stat3 nuclear translocation at 10 uM in both BHK-21 and U2-OS cells.

SD169 is an orally available, ATP-competitive, isoenzyme-selective Mitogen-Activated Protein Kinase (MAPK) inhibitor.

SDZ 220-581 Hcl is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).

SDZ 220-581 is a potent, competitive antagonist at the NMDA glutamate receptor subtype(pKi= 7.7).

SDZ 220-581 is a potent, competitive NMDA receptor antagonist with pKi of 7.7, fully protects against maximal electroshock seizures (MES) at oral doses of 10 mg/kg in rats and in mice. .

SDZ285428 is a CYP51 inhibitor. SDZ285428 inhibits Trypanosoma cruzi (TC) CYP51 with I/E2 <1 (5 min) and I/E2=9 (1 h). SDZ285428 inhibits Trypanosoma brucei (TB) CYP51 with I/E2 <1 (5 min) and I/E2=35 (1 h).

SecinH3 is a selective cytohesin inhibitor with IC50 of 2.4 μM, 5.4 μM, 5.4 μM, 5.6 μM, 5.6 μM, and 65 μM for hCyh2, hCyh1, mCyh3, hCyh3, drosophila steppke, and yGea2-S7, respectively.

Seco-rapamycin is the first in vivo open-ring metabolite of rapamycin that does not affect mTOR..

SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.

SEL120-34A is an ATP-competitive, selective, orally active CDK8 inhibitor that inhibits kinase activities of CDK8/CycC and CDK19/CycC complexes with IC50 of 4.4 nM and 10.4 nM, respectively.

SEL-201 (SLV-2436, SEL201-88) is a novel potent, selective, ATP-competitive and oral MNK1/2 inhibitor with IC5010.8/5.4 nM, respectively.

SEL24-B489 (SEL24) is a potent, dual PIM and FLT3-ITD inhibitor with Kd of 2/2/3 nM for PIM1/2/3, Kd of 160/16 nM for FLT3-WT/FLT3-ITD, respectively.

SEL24-B489 (SEL24) is a potent, dual PIM and FLT3-ITD inhibitor with Kd of 2/2/3 nM for PIM1/2/3, Kd of 160/16 nM for FLT3-WT/FLT3-ITD, respectively.

Selective AMPA receptor antagonist (Ki values are 84, 2200 and > 37000 nM For AMPA, kainate and NMDA receptors respectively). Neuroprotective.

RO-3 is a potent, CNS-penetrant, and orally active P2X3 and P2X2/3 antagonist with pIC50s of 5.9 and 7.0 for human homomultimeric P2X3 and heteromultimeric P2X2/3 receptors, respectively. RO-3 shows selectivity for P2X3 and P2X2/3 over all other functional homomultimeric P2X receptors (IC50 >10 μM at P2X1,2,4,5,7)[1].

Selective reverse transcriptase inhibitor. Exhibits 100-fold selectivity for HIV reverse transcriptase over DNA polymerase α.

Seletalisib (UCB5857) is potent and selective PI3Kδ inhibitor with an IC50 of 12 nM.

Selgantolimod is a novel toll-​like receptor TLR8 modulator for the treatment of HIV infection..

Seliforant (SENS-111, SENS111) is a novel potent, selective histamine H4 receptor antagonist..

Selurampanel (BGG 492) is a selective, orally active and competitive AMPA receptor (AMPAR) antagonist with IC50 of 0.19 uM.

Semagacestat (LY450139) is a γ-secretase blocker for Aβ42, Aβ40 and Aβ38 with IC50 of 10.9 nM, 12.1 nM and 12.0 nM, also inhibits Notch signaling with IC50 of 14.1 nM.

Semapimod (CNI 1493.

Semapimod (CNI 1493.

SEMBL is a potent NF-κB inhibitor that inhibits DNA binding of NF-κB component p65.

Sembragiline (RO4602522, RG1577, EVT 302) is a novel potent, selective, orally available monoamine oxidase B (MAO-B) inhibitor with IC50 of 5.9 nM, >600-fold selectivity over MAO-A.

SEN1269 is a novel potent Aβ aggregation inhibitor that binds to monomeric Aβ1-42 with Kd of 4.4 uM, protects neuronal cell lines against an Aβ1-42 insult with IC50 of 15 uM.

Senexin A is a potent and selective inhibitor of CDK8 and its nearest relative, CDK19 with Kd values of 0.83 μM and 0.31 μM for CDK8 and CDK19 ATP site binding, respectively.

Senktide is a potent, selective agonist of neuromedin K3 (NK3) receptor (EC50 =0.5-3 nM), less potently agonizes the NK1 receptor (EC50=35 µM) and is without effect on the NK2 receptor..

Sephin 1 (NSC 65390) is a selective inhibitor of PPP1R15A that disrupts the PPP1R15A-PP1c complex but spares the related PPP1R15B-PP1c complex.

Sepin-1 is a small molecule, noncompetitive separase inhibitor with IC50 of 14.8 uM.

Seratrodast(AA 2414) is a potent and selective thromboxane A2 receptor (TP) antagonist.

SERCA2a activator A is a novel sarco/endoplasmic reticulum Ca2+-dependent ATPase 2a (SERCA2a) activator that activates the Ca2+-dependent ATPase activity of cardiac SR vesicles but not that of skeletal muscle SR vesicles that lack of phospholamban (PLN).

Serdexmethylphenidate is the dextrorotary form of methylphenidate and a norepinephrine-dopamine reuptake inhibitor (NDRI) and thus a psychostimulant..

Sermorelin is a Growth Hormone Releasing Hormone (GHRH) produced by the brain that stimulates the production and release of Growth Hormone (GH).

Setafrastat is a small molecule hair growth stimulator.

Setiptiline is a serotonin receptor antagonist.

Setiptiline(Org-8282) is a serotonin receptor antagonist.

Setrobuvir (ANA-598) is an experimental drug candidate For the treatment of hepatitis C. It was discovered at Anadys Pharmaceuticals. In 2011, Roche acquired Anadys in order to develop setrobuvir. It is currently in Phase IIb clinical trials, used in combination with interferon and ribavirin, targeting hepatitis C patients with genotype 1.For the detailed information of Setrobuvir, the solubility of Setrobuvir in water, the solubility of Setrobuvir in DMSO, the solubility of Setrobuvir in PBS buffer, the animal experiment (test) of Setrobuvir, the cell expriment (test) of Setrobuvir, the in vivo, in vitro and clinical trial test of Setrobuvir, the EC50, IC50,and Affinity of Setrobuvir, Please contact DC Chemicals..

Sevelamer is a phosphate binding drug used to treat hyperphosphatemia in patients with chronic kidney disease; consists of polyallylamine that is crosslinked with epichlorohydrin.

SF 2312 is a highly potent, low-nanomolar inhibitor of Enolase with IC50 of 37.9 nM and 42.5 nM for recombinant hENO1 and hENO2 respectively.

SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8.

SF-1126 is a pan PI3K/BRD4 inhibitor, RGDS-conjugated LY294002 prodrug that exhibits increased solubility and binds to specific integrins.

SFV785 (SRPIN-785) is a derivative of SRPIN340 that selectively inhibits NTRK1 and MAPKAPK5 kinase, shows anti-viral activity on HCV, DENV and yellow fever viruses.

SG3199 is a PBD dimer warhead component of antibody-drug conjugate (ADC) payload tesirine, demonstrates potently cytotoxic against a panel of human solid tumour and haematological cancer cell lines with mean GI50 of 151.5 pM.

SG85 is a potent Enterovirus 3C protease inhibitor with EC50 of 180 nM against EV71 and 60 nM against human rhinovirus 14 in a live virus-cell-based assay.

SGC3027 is a histone methyltransferase inhibitor. SGC3027 is the first potent, selective and cell active chemical probe for PRMT7.

SGC-CBP30 is a potent CREBBP/EP300 inhibitor with IC50 of 21 nM and 38 nM, respectively.

SGC-iMLLT is the first small molecule chemical probe for the YD of MLLT1 (ENL/YEATS1) and MLLT3 (AF9/YEATS3) with Kd of 129 and 77 nM respectively, IC50 of 0.26 uM (MLLT1).

SGD-1882 (PBD dimer, Pyrrolobenzodiazepine dimer) is a novel potent DNA-intercalating payload dimer (PBD dimer) payload for antibody-drug conjugates (ADCs)..

SGN-2FF is an orally bioavailable small molecule inhibitor of glycoprotein fucosylation, demonstrates encouraging preclinical antitumor activity in mouse models.

SGPL1-IN-28 is a novel S1P lyase inhibitor with in vitro IC50 of 120 nM, cell IC50 of 230 nM..

SGX-523 is a selective Met inhibitor with IC50 of 4 nM, no activity to BRAFV599E, c-Raf, Abl and p38α.

SH-BC-893 is a water-soluble, orally bioavailable synthetic sphingolipid that triggers nutrient transporter internalization and also blocks lysosome-dependent nutrient generation pathways in cancer cells, activates protein phosphatase 2A (PP2A), leading to mislocalization of the lipid kinase PIKfyve; selectively kills cells expressing an activated form of the anabolic oncogene Ras in vitro and in vivo.SH-BC-893, increases the activity of antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) up to 200-fold in vitro without permeabilizing endosomes. SH-BC-893 treatment trapped endocytosed oligonucleotides within extra-lysosomal compartments thought to be more permeable due to frequent membrane fission and fusion events. Simultaneous disruption of ARF6-dependent endocytic recycling and PIKfyve-dependent lysosomal fusion was necessary and sufficient for SH-BC-893 to increase non-lysosomal oligonucleotide levels and enhance their activity. In mice, oral administration of SH-BC-893 increased ASO potency in the liver by 15-fold without toxicity. More importantly, SH-BC-893 enabled target RNA knockdown in the CNS and lungs of mice treated subcutaneously with cholesterol-functionalized duplexed oligonucleotides or unmodified ASOs, respectively. Together, these results establish the feasibility of using a small molecule that disrupts endolysosomal trafficking to improve the activity of oligonucleotides in extrahepatic tissues.

Shield-1 analog is a derivative of Shield-1,a cell-permeable FKBP ligand that is designed to protect an otherwise unstable protein domain from degradation; binds tightly to FKBP, induces rapid and processive degradation of the LID domain.

SHP2 inhibitor 14 is a novel potent, selective, allosteric, orally acitve SHP2 inhibitor with IC50 of 28 nM.

SHP2 inhibitor 8 is a potent, selective inhibitor of SHP2 with IC50 of 5 nM, inhibits p-ERK in KYSE520 cells with IC50 of 5 nM.

SHP2 inhibitor 9 is a potent, selective inhibitor of SHP2 with IC50 of 48 nM, inhibits p-ERK in KYSE520 cells with IC50 of 28 nM.

SHP2 inhibitor LY6 (LY6) is a small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2, inhibits SHP2 with IC50 of 9.8 uM, 7-fold selectivity over SHP1.

SHP244 is a distinct, allosteric site 2 SHP2 inhibitor with IC50 of 60 uM (SHP2 1-525), equipotent on the double mutant (SHP2T253M/Q257L IC50=68 uM), and selective over the phosphatase domain (SHP2 PTP IC50>100 uM)..

SHP2-IN-2 is a selective, allosteric inhibitor of protein tyrosine phosphatase SHP2, preferentially inhibits SHP2 F285S over the PTP domain and allosteric site mutant.

SHP389 (SHP-389, SHP 389) is a novel potent, selective, allosteric SHP2 inhibitor with IC50 of 36 nM, shows with impressive hERG selectivity (IC50>30 uM).

SHP504 is a distinct, allosteric site 2 SHP2 inhibitor with IC50 of 21 uM (SHP2 1-525), and selective over the phosphatase domain (SHP2 PTP IC50>100 uM).downregulates DUSP6 mRNA, a downstream MAPK pathway marker, in KYSE-520 cancer cells.

SHP836 is a distinct, allosteric site 2 SHP2 inhibitor with IC50 of 12 uM (SHP2 1-525), and selective over the phosphatase domain (SHP2 PTP IC50>100 uM).downregulates DUSP6 mRNA, a downstream MAPK pathway marker, in KYSE-520 cancer cells.

SHP844 is a distinct, allosteric site 2 SHP2 inhibitor with IC50 of 18.9 uM (SHP2 1-525), and selective over the phosphatase domain (SHP2 PTP IC50>100 uM).downregulates DUSP6 mRNA, a downstream MAPK pathway marker, in KYSE-520 cancer cells; enhances pharmacological pathway inhibition in cells combined with SHP099.

SHR3824 is a potent, selective SGLT2 inhibitor with IC50 of 2.38 nM, >1000-fold selectivity over SGLT1.

SI-2 (EPH-116) is a potent small-molecule inhibitor of steroid receptor coactivator-3 (SRC-3 or AIB1) that can selectively inhibit the intrinsic transcriptional activities of SRC-3, also inhibits SRC-1 and SRC-2.

SIG-1191 (SIG1191) is a soprenylcysteine (IPC) small molecule with anti-inflammatory activity, inhibits UVB-induced inflammation blocking pro-inflammatory cytokine interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α) production.

SIG1459 (SIG-1459) is a novel anti-acne isoprenylcysteine (IPC) small molecule that shows direct antibacterial activity and inhibits TLR2 inflammatory signaling.

Sigma1-IN-4 is a novel small molecule sigma-1 receptor inhibitor with Ki of 38 nM.

Sildenafil Mesylate is a mesylate form of Sildenafil, an inhibitor of Phosphodiesterase 5.

Silvestrol is a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in cancer cells through the mitochondrial/apoptosome pathway.

Silvestrol is a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in cancer cells through the mitochondrial/apoptosome pathway.

Simeprevir (TMC 435350) is a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM).

Simmiparib is a novel potent, orally active PARP1/2 inhibitor with IC50 of 1.75/0.22 nM, inhibits PARP1 >90-fold more potently than the other PARPs (PARP3, TNKS1, TNKS2).

Simotinib (SIM-6802) is a novel potent EGFR inhibitor for treatment of NSCLC..

Simvastatin (MK 733) is a competitive inhibitor of HMG-CoA reductase with a Ki of 0.2 nM.

Sinapinic acid (Sinapic acid) is a phenolic compound isolated from Hydnophytum formicarum Jack. Rhizome, acts as an inhibitor of HDAC, with an IC50 of 2.27 mM, and also inhibits ACE-I activity. Sinapinic acid posssess potent anti-tumor activity, induces a

Sincalide (CCK-8) is a 8-amino acid C-terminal fragment of cholecystokinin.

SINCRO is a novel anti-cancer compound that can activate the cytosolic DNA-sensing STING signaling pathway leading to the induction of type I interferon (IFN) genes.

Sinefungin (A 9145.

Siomycin A (NSC 285116) is an antibiotic thiazole inhibitor of the oncogenic transcription factor FOXM1, down-regulates the transcriptional activity as well as the protein and mRNA abundance of FoxM1.

SirReal2 is a potent and selective Sirt2 inhibitor with IC50 of 140 nM.

SirT1 enhancer A03 is a specific, orally bioavailable, brain penetrant apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, increases the levels of the neuroprotective enzyme SirT1 while not affecting levels of neurotoxic SirT2 in vitro in ApoE4-

SIRT2 inhibitor AEM2 (AEM2) is a selective SIRT2 inhibitor with IC50 of 3.8 uM, shows only weak effects on other sirtuins such as SIRT1, SIRT3, and yeast Sir2.

SIRT5 inhibitor is a potent Human Sirtuin 5 deacylase inhibitor, with an IC50 of 0.11 μM.

Sitagliptin phosphate (MK-0431) is a potent inhibitor of DPP-IV with IC50 of 19 nM in Caco-2 cell extracts.

Sitravatinib (MGCD516) is a novel small molecule inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Kit, PDGFRβ, PDGFRα, c-Met, and Axl.

SJ-172550 is the first MDMX inhibitor with EC50 of 0.84 uM; binds reversibly to MDMX and effectively kills retinoblastoma cells in which the expression of MDMX is amplified.

SJ-733 (SJ000557733.

SJ830599 is a modest selective BRD2-BD2 inhibitor with IC50 of 0.61 uM, 3.3-fold selectivity over BRD2-BD1.